Afrezza: Phase II/III data

Pooled data from 4,467 Type I and II diabetics in 9 Phase II/III trials showed that Afrezza did not lead to an increased risk of cardiovascular events compared to control groups in which patients received various other diabetes medications (198 vs. 171 events, RR=1.01). Data were presented at the American Diabetes Association meeting in San Diego. ...